146 related articles for article (PubMed ID: 9644630)
1. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis.
Tomasoni S; Noris M; Zappella S; Gotti E; Casiraghi F; Bonazzola S; Benigni A; Remuzzi G
J Am Soc Nephrol; 1998 Jul; 9(7):1202-12. PubMed ID: 9644630
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan-induced cyclooxygenase-2 expression promotes thromboxane A2 production by renal cells.
Sun LK; Beck-Schimmer B; Oertli B; Wüthrich RP
Kidney Int; 2001 Jan; 59(1):190-6. PubMed ID: 11135071
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis.
Hartner A; Pahl A; Brune K; Goppelt-Struebe M
Inflamm Res; 2000 Jul; 49(7):345-54. PubMed ID: 10959556
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G
Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
[TBL] [Abstract][Full Text] [Related]
5. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.
Oates JC; Halushka PV; Hutchison FN; Ruiz P; Gilkeson GS
Am J Med Sci; 2011 Feb; 341(2):101-5. PubMed ID: 20924284
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclooxygenase-2 in biopsies obtained from human transplanted kidneys undergoing rejection.
Hausknecht B; Voelkl S; Riess R; Gauer S; Goppelt-Struebe M
Transplantation; 2003 Jul; 76(1):109-14. PubMed ID: 12865795
[TBL] [Abstract][Full Text] [Related]
7. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney.
Fujihara CK; Antunes GR; Mattar AL; Andreoli N; Malheiros DM; Noronha IL; Zatz R
Kidney Int; 2003 Dec; 64(6):2172-81. PubMed ID: 14633140
[TBL] [Abstract][Full Text] [Related]
9. Eicosanoid synthesis in peripheral blood monocytes: a marker of disease activity in lupus nephritis.
Menè P; Pecci G; Cinotti GA; Pugliese G; Pricci F; Pugliese F
Am J Kidney Dis; 1998 Nov; 32(5):778-84. PubMed ID: 9820447
[TBL] [Abstract][Full Text] [Related]
10. [Apoptosis and expressions of PDCD5 and Caspase-3 in renal tissues of children with lupus nephritis].
Li X; Huang JP; Ding J
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):517-20. PubMed ID: 16083554
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells.
Shiokoshi T; Ohsaki Y; Kawabe J; Fujino T; Kikuchi K
J Hypertens; 2002 Mar; 20(3):455-61. PubMed ID: 11875313
[TBL] [Abstract][Full Text] [Related]
12. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse).
Câmpean V; Theilig F; Paliege A; Breyer M; Bachmann S
Am J Physiol Renal Physiol; 2003 Jul; 285(1):F19-32. PubMed ID: 12657565
[TBL] [Abstract][Full Text] [Related]
13. Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis.
Hirose S; Yamamoto T; Feng L; Yaoita E; Kawasaki K; Goto S; Fujinaka H; Wilson CB; Arakawa M; Kihara I
J Am Soc Nephrol; 1998 Mar; 9(3):408-16. PubMed ID: 9513902
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors.
Penglis PS; Cleland LG; Demasi M; Caughey GE; James MJ
J Immunol; 2000 Aug; 165(3):1605-11. PubMed ID: 10903770
[TBL] [Abstract][Full Text] [Related]
15. Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients.
Ma R; Jiang W; Li Z; Sun Y; Wei Z
Lupus; 2016 Dec; 25(14):1577-1586. PubMed ID: 27147620
[TBL] [Abstract][Full Text] [Related]
16. Expression of DNA topoisomerases in chronic proliferative kidney disease.
Ivanova LV; Rudolph P; Kellner U; Jürgensen A; Tareeva IE; Alm P; Proppe D
Kidney Int; 2000 Oct; 58(4):1603-12. PubMed ID: 11012894
[TBL] [Abstract][Full Text] [Related]
17. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
Yoshida T; Ichikawa Y; Tojo T; Homma M
Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of prostanoid forming enzymes along the rat nephron.
Vitzthum H; Abt I; Einhellig S; Kurtz A
Kidney Int; 2002 Nov; 62(5):1570-81. PubMed ID: 12371957
[TBL] [Abstract][Full Text] [Related]
19. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.
Wilson HR; Medjeral-Thomas NR; Gilmore AC; Trivedi P; Seyb K; Farzaneh-Far R; Gunnarsson I; Zickert A; Cairns TD; Lightstone L; Cook HT; Pickering MC
Kidney Int; 2019 Mar; 95(3):655-665. PubMed ID: 30655025
[TBL] [Abstract][Full Text] [Related]
20. Analysis of renal immunoexpression of cyclooxygenase-1 and cyclooxygenase-2 in lupus and nonlupus membranous glomerulopathy.
Danilewicz M; Wagrowska-Danilewicz M
Pol J Pathol; 2007; 58(4):221-6. PubMed ID: 18459455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
